Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:INBX NASDAQ:PMVP NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$4.17+1.7%$3.95$3.04▼$8.35$224.31M1.21167,188 shs104,912 shsINBXInhibrx Biosciences$23.62-0.1%$15.19$10.80▼$24.30$342.36M-0.0497,459 shs103,799 shsPMVPPMV Pharmaceuticals$1.33-0.7%$1.05$0.81▼$1.82$69.62M1.49199,008 shs115,372 shsTVGNSemper Paratus Acquisition$1.24+0.8%$1.23$0.26▼$3.09$226.19M-0.735.07 million shs596,386 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+4.06%-0.49%+3.02%+24.24%-50.96%INBXInhibrx Biosciences+3.01%+13.05%+61.76%+106.19%+64.12%PMVPPMV Pharmaceuticals+0.75%+3.88%+25.23%+31.37%-20.24%TVGNSemper Paratus Acquisition+2.50%-0.81%-3.15%+25.56%+68.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote3.3241 of 5 stars3.52.00.00.02.73.31.3INBXInhibrx Biosciences2.5869 of 5 stars0.03.00.04.62.22.51.3PMVPPMV Pharmaceuticals3.1933 of 5 stars3.53.00.00.03.32.50.6TVGNSemper Paratus Acquisition4.1266 of 5 stars3.55.00.00.01.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.0091.85% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/APMVPPMV Pharmaceuticals 3.00Buy$5.50313.53% UpsideTVGNSemper Paratus Acquisition 3.00Buy$10.00706.45% UpsideCurrent Analyst Ratings BreakdownLatest PMVP, TVGN, BTMD, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/10/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/12/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M1.16$0.78 per share5.35($2.78) per share-1.50INBXInhibrx Biosciences$200K1,710.09$118.10 per share0.20$9.23 per share2.56PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.616.847.72N/A10.93%-19.44%20.12%8/6/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)TVGNSemper Paratus Acquisition-$13.73MN/A0.00∞N/AN/AN/A-934.56%8/4/2025 (Estimated)Latest PMVP, TVGN, BTMD, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BTMDbiote$0.06N/AN/AN/A$49.52 millionN/A8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/12/2025Q2 2025INBXInhibrx Biosciences-$2.92N/AN/AN/AN/AN/A5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.421.14INBXInhibrx Biosciences1.045.125.12PMVPPMV PharmaceuticalsN/A16.7516.75TVGNSemper Paratus AcquisitionN/A0.350.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%INBXInhibrx Biosciences82.46%PMVPPMV Pharmaceuticals90.20%TVGNSemper Paratus AcquisitionN/AInsider OwnershipCompanyInsider OwnershipBTMDbiote24.00%INBXInhibrx Biosciences17.09%PMVPPMV Pharmaceuticals7.57%TVGNSemper Paratus Acquisition73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million41.58 millionNot OptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionablePMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionableTVGNSemper Paratus Acquisition3183.89 million49.21 millionN/APMVP, TVGN, BTMD, and INBX HeadlinesRecent News About These CompaniesTevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing FacilityJuly 17 at 9:15 AM | globenewswire.comTevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha LaunchJuly 16 at 11:57 AM | globenewswire.comTevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development CostsJuly 14 at 9:30 AM | globenewswire.comTevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate InnovationJuly 10, 2025 | globenewswire.comTevogen Bio Holdings Inc News (TVGN) - Investing.comJuly 8, 2025 | investing.comSemper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's WhyJuly 2, 2025 | marketbeat.comTevogen CEO Contributes to Build-Out and First-Year Operations of New HeadquartersJune 30, 2025 | globenewswire.comSemper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalJune 18, 2025 | marketbeat.comTevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target DiscoveryJune 18, 2025 | globenewswire.comTevogen BioJune 17, 2025 | thepharmaletter.comTTevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars InitiativesJune 12, 2025 | nasdaq.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10, 2025 | nasdaq.comTevogen Bio doubles Warren HQ footprint for AI expansionJune 10, 2025 | njbiz.comNAmbitious Tevogen makes expansion announcementJune 10, 2025 | thepharmaletter.comTRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10, 2025 | insidertrades.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9, 2025 | globenewswire.comtevogen bio expands office lease in new jersey with key amendmentJune 5, 2025 | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4, 2025 | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI TechnologiesMay 30, 2025 | quiverquant.comQTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMVP, TVGN, BTMD, and INBX Company Descriptionsbiote NASDAQ:BTMD$4.17 +0.07 (+1.71%) Closing price 04:00 PM EasternExtended Trading$4.18 +0.01 (+0.24%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Inhibrx Biosciences NASDAQ:INBX$23.62 -0.03 (-0.13%) Closing price 04:00 PM EasternExtended Trading$23.58 -0.05 (-0.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.PMV Pharmaceuticals NASDAQ:PMVP$1.33 -0.01 (-0.75%) Closing price 04:00 PM EasternExtended Trading$1.33 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Semper Paratus Acquisition NASDAQ:TVGN$1.24 +0.01 (+0.81%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.48%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
